awmsg logo



dalbavancin (Xydalba®)


Reference No. 2001


Appraisal information

dalbavancin (Xydalba®) 500 mg powder for concentrate for solution for infusion


Company: Cardiome UK Ltd
BNF category: Infections
NMG meeting date: 13/06/2018
AWMSG meeting date: 18/07/2018
   
   
Submission Type: Full Submission
Status: In progress
Advice No: Not available
Ratification by Welsh Government: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults
Preliminary Appraisal Recommendation (PAR)
Download
Company Response to the Preliminary Appraisal Recommendation (CR PAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download